Business Standard

Thursday, December 19, 2024 | 10:09 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Monkeypox bite: Bavarian Nordic is becoming a 'hot stock' again

Shares in the Danish biotech, which makes the only monkeypox vaccine approved by the US Food and Drug Administration, have gained 69% since hitting a low in early May

Bavarian Nordic
Premium

Analysts covering the stock are also positive, with eight of the nine firms tracked by Bloomberg rating Bavarian Nordic a buy.

Jonas Ekblom & Christian Wienberg | Bloomberg
Bavarian Nordic A/S is having a bit of a meme-stock moment, with retail traders buying up shares in the monkeypox vaccine maker as cases of the virus steadily rise.

Shares in the Danish biotech, which makes the only monkeypox vaccine approved by the US Food and Drug Administration, have gained 69% since hitting a low in early May. At the same time, cases of the virus have jumped from just a handful in Europe at the start of last month to more than 1,200 cases, mostly in men, across the region, as well as in the Americas, the Middle East, and

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in